title: An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder.
abstract: BACKGROUND
  The prevalence of major depressive disorder (MDD) in human immunodeficiency virus (HIV)-seropositive patients is higher than in the general population. The treatment of comorbidities of HIV infection, such as depression, is an important target in the clinical management of these patients. The use of antidepressants in HIV patients can be complicated by the pharmacokinetic interaction between antidepressants and antiretroviral agents. Several antidepressants and antiretrovirals are metabolized by cytochrome P450 (CYP450). Reboxetine is a noradrenergic antidepressant that is not metabolized by CYP450 and may offer a valuable option in the treatment of MDD in HIV-seropositive patients.
  
  
  METHODS
  Twenty HIV-infected outpatients with MDD according to DSM-IV criteria were treated with reboxetine, 8 mg/day, for 12 weeks within an open trial design. Outcome measures included the Montgomery-Asberg Depression Rating Scale (MADRS) and a side effect profile. Data were gathered from July 2000 to March 2001.
  
  
  RESULTS
  Seventy-five percent of patients (N = 15) completed the trial. All patients who completed the trial had an improvement equal to or higher than a 50% reduction in their MADRS scores at endpoint. The most frequent adverse effects were insomnia, sweating, and shivering.
  
  
  CONCLUSIONS
  Within this open trial, reboxetine was found to be effective in reducing depressive symptoms in HIV illness. The rate of dropout (25%) suggests that reboxetine may be well tolerated in this population.
authors.affiliation: Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. adrianacarvalhal@terra.com.br
authors.forename: Adriana S
authors.initials: AS
authors.lastname: Carvalhal
authors.forename: Paulo Belmonte
authors.initials: PB
authors.lastname: de Abreu
authors.forename: Alessandra
authors.initials: A
authors.lastname: Spode
authors.forename: Joel
authors.initials: J
authors.lastname: Correa
authors.forename: Flavio
authors.initials: F
authors.lastname: Kapczinski
mesh_terms: D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000553:Ambulatory Care; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015897:Comorbidity; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D005260:Female; D006679:HIV Seropositivity / Q000453:epidemiology*; D006801:Humans; D006945:Hyperhidrosis / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced; D011569:Psychiatric Status Rating Scales; D000077593:Reboxetine; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D016896:Treatment Outcome
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D009025:Morpholines; D000077593:Reboxetine